Angioline will launch new products to the market

Moscow, June 9, 2016.

On the threshold of the TCT Russia 2016, ANGIOLINE Company declared its plans to launch a new bioresorbable drug-eluting stent. Moreover, by the end of 2016, ANGIOLINE is going to complete the process of localizing manufacture of guiding catheters and guidewires that will allow to extend the company’s offer portfolio greatly and to become more deeply involved into the product improvement.

A new bioresorbable drug-eluting stent will be targeted to both the Russian market and the markets of Europe and Asia. Specially for this purpose the company has initiated the procedure of obtaining the CE mark, a special Certificate indicating conformance of ANGIOLINE’s products with the European quality standards. The Certificate will cover quite a wide range of company’s products and first of all stents and balloon catheters.

President of ANGIOLINE, Andrey Kudryashov, noted that “In Russia there is no single source of bioresorbable drug-eluting stents.” “The Ministry of Public Health set a standard of medical aid in unstable angina and ACS which determines the use of resorbable stents twice as often as those non-resorbable. This opens up rather wide possibilities to stent manufacturers of such stents, since from year to year ACS incidence is not going to decrease”.